The effect of conjugated linoleic acid and omega 3 fatty acids on patients with atheroscherosis.

Evaluation the effect of conjugated linoleic acid and omega 3 fatty acids supplements on lipid profile, inflammatory factors and oxidative stress indices on patients with atherosclerosis

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201103146067N1

Enrollment

Registered

2011-05-04

Start date

2011-02-11

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart disease. ?????? ???? ?????????????

Interventions

Intervention 1: Conjugated linoleic acid intake,3000 mg per day, for 2months , 3 capsule per day, each capsule contain 1000mg cnjugated linoleic acid. Intervention 2: Omega 3 fatty acids intake,1920

Treatment - Drugs

Placebo

Conjugated linoleic acid intake,3000 mg per day, for 2months , 3 capsule per day, each capsule contain 1000mg cnjugated linoleic acid

Omega 3 fatty acids intake,1920mg per day for 2 months , 3 capsule per day, each capsule contain 640 mg,omega3 fatty acids

Placebo intake for 2 months , 3 capsule per day

Eligibility

Sex/Gender

All

Age

30 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with Atherosclerosis with Age more than30 years old, 24.5>Body Mass Index>18.5, use of stable dosage medication for hyperlipidemia in study period, patients with history of stable angina, heart attack and bypass surgery. Exclusion criteria: Having Acute heart failure ? Arrhythmia, Acute complications of atherosclerosis, using any supplement such as vitamin C, E, Omega3 during and six months before the study, pregnancy , UVB exposure with therapeutic goals and diabetes mellitus

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Lipid profile. Timepoint: Before and after intervention. Method of measurement: Auto Analysor.	—

Secondary

Measure	Time frame
GSH-X(Glutathione peroxidase). Timepoint: Before and after intervention. Method of measurement: ELIZA.;MDA (Malondialdehyde). Timepoint: Before and after intervention. Method of measurement: Spectrophotometery.;Hs-CRP(high sensetive c-reactive protein). Timepoint: Before and after intervention. Method of measurement: ELIZA.;Interleukin 6. Timepoint: Before and after intervention. Method of measurement: RIA kit.	—

Measure

Time frame

GSH-X(Glutathione peroxidase). Timepoint: Before and after intervention. Method of measurement: ELIZA.;MDA (Malondialdehyde). Timepoint: Before and after intervention. Method of measurement: Spectrophotometery.;Hs-CRP(high sensetive c-reactive protein). Timepoint: Before and after intervention. Method of measurement: ELIZA.;Interleukin 6. Timepoint: Before and after intervention. Method of measurement: RIA kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactfereshte aliasghari

School of health and nutrition, Shiraz University of Mediccal Sciences

f.aliasghary@yahoo.com+98 71 1725 1001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026